Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH) from its SEC filings: 2025 revenue $719.9 million (-2% vs the year before), net margin 14%, free cash flow $121.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $719.9 million |
| Revenue growth | -2% |
| Net income | $98.1 million |
| Net margin | 13.6% |
| Free cash flow | $121.2 million |
| Diluted EPS | $2.03 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +5% |
| Cash | $223.6 million |
| Long-term debt | $619.7 million |
| Share count, 1 year | -8% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.